We speculated two possibilities that might prevent durable tumor control when combining ACT of PBMC and dual PD1/CTLA4 blockade despite continual delivery of IL2 throughout the study: (1) low frequency of tumor-specific T cells in the PBMC, (2) the life-span or quality of transferred T cells in the NSG mice. Here, CTLA4 is linked to neoplasm.